Metex (Methotrexate)

Methotrexate blocks the enzyme dihydrofolate reductase, preventing the formation of tetrahydrofolate needed for DNA and RNA synthesis. By limiting nucleotide production, it reduces the proliferation of rapidly dividing cells, including immune cells that drive inflammation and cancer cells that drive tumor growth.

The specific dose of Metex is individualized by the prescribing clinician based on the patient’s diagnosis, disease severity, renal and hepatic function, and other clinical factors. The prescriber determines the appropriate amount, frequency, and duration of therapy.

Methotrexate is classified as pregnancy category X because it can cause severe fetal malformations and embryotoxicity. It is contraindicated in pregnancy, and effective contraception is required for both men and women of reproductive potential. Use while breastfeeding is also discouraged due to potential infant exposure.

To request Metex, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain logistics if needed), and any required import documentation.

Methotrexate differs from biologic agents such as TNF‑α inhibitors by acting as a small‑molecule antimetabolite that directly interferes with DNA synthesis. It is generally less expensive and can be administered subcutaneously, but it may have a broader toxicity profile, requiring regular laboratory monitoring, whereas biologics target specific cytokines with different safety considerations.

Metex should be stored refrigerated at 2‑8 °C. Keep the vial in its original packaging, protect it from light, and avoid freezing or shaking the solution. If a temporary temperature excursion occurs, follow the manufacturer’s guidance before use.

Metex is supplied as a sterile solution for injection and is administered subcutaneously. The injection is typically given into the abdomen or thigh using a suitable needle. Administration technique, site rotation, and aseptic precautions should follow the prescribing clinician’s instructions.

The most serious risks include severe liver toxicity, pulmonary fibrosis, bone marrow suppression leading to pancytopenia, and teratogenic effects. Patients should be monitored closely for signs of hepatic dysfunction, respiratory symptoms, unexplained bruising or infections, and must avoid pregnancy throughout treatment and for a defined period after discontinuation.

Metex is contraindicated in individuals with known hypersensitivity to methotrexate, active severe liver disease, significant renal impairment, uncontrolled infections, and in all pregnant women. It should also be used with caution or avoided in patients with pre‑existing blood dyscrasias, pulmonary disease, or those taking interacting medications that could increase toxicity.